Do you see GLP-1 receptor agonists as a potential adjunctive therapy in patients with T2-low asthma and obesity who remain symptomatic on ICS-LABA, prior to escalation to tezepelumab?

Initial research is promising but needs more data.

The answer may be a bit convoluted. There is a small literature that demonstrates that obese type 2 diabetes patients with asthma have better control with fewer exacerbations when taking GLP-1RAs compared to other therapies such as DPP-4I, SGLT2I, metformin, or insulin. These observations are mostly...